This site contains promotional information intended only for healthcare professionals resident in the United Kingdom
Example content
Adverse event reporting can be found at the bottom of the page
Prescribing information can be found at the bottom of the page.
Join us on 12 November 2025 to hear from Dr Faisal Basheer, Consultant Heamatologist, Dr Andrew King, Consultant Heamatologist, Dr Marquita Camilleri, Consultant Heamatologist and Gini Melesi, East of England Cancer Alliance Transformation Lead, discussing 'Elrexfio®▼(elranatamab), a BCMA Directed Bispecific Immunotherapy, CUH Experience in Ambulatory Care Service for delivery of Bi-specifics in Relapsed Refractory Multiple Myeloma & NHS 10 Year Strategy Policy Debrief' followed by a live interactive Q&A.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and will include reference to medicines promoted by Pfizer.
This meeting is available to join virtually or in-person. Please register your interest to attend and further information will be sent to you.
Prescribing information can be found at the bottom of the page.
Join us on 12 November 2025 to hear from Dr Faisal Basheer, Consultant Heamatologist, Dr Andrew King, Consultant Heamatologist, Dr Marquita Camilleri, Consultant Heamatologist and Gini Melesi, East of England Cancer Alliance Transformation Lead, discussing 'Elrexfio®▼(elranatamab), a BCMA Directed Bispecific Immunotherapy, CUH Experience in Ambulatory Care Service for delivery of Bi-specifics in Relapsed Refractory Multiple Myeloma & NHS 10 Year Strategy Policy Debrief' followed by a live interactive Q&A.
This promotional meeting is organised and funded by Pfizer Ltd for UK HCPs and will include reference to medicines promoted by Pfizer.
This meeting is available to join virtually or in-person. Please register your interest to attend and further information will be sent to you.
No biography available
No biography available
No biography available
No Biography Available.
Elrexfio®▼(elranatamab)
ELREXFIO® (elranatamab) has a conditional marketing authorisation. A conditional marketing authorisation means that further evidence of efficacy and safety data are being collected. New information on this medicinal product will be reviewed when any relevant information of significance becomes available and at least every year.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to Pfizer Medical Information on 01304 616161.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2025 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024.